NCT05736367 Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
| NCT ID | NCT05736367 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rutgers, The State University of New Jersey |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 16 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 16 participants in total. It began in 2024-11-15 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Eligibility Criteria
Inclusion Criteria: * Have hormone receptor (HR) positive \[estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy. * Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0) * Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy). * Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection. Exclusion Criteria: * Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. * Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer. * Concomitant active malignancy * Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)
Contact & Investigator
Coral Omene, MD, PhD
PRINCIPAL INVESTIGATOR
Cancer Institute of New Jersey Rutgers
Frequently Asked Questions
Who can join the NCT05736367 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05736367 currently recruiting?
Yes, NCT05736367 is actively recruiting participants. Contact the research team at co273@cinj.rutgers.edu for enrollment information.
Where is the NCT05736367 trial being conducted?
This trial is being conducted at New Brunswick, United States, New Brunswick, United States.
Who is sponsoring the NCT05736367 clinical trial?
NCT05736367 is sponsored by Rutgers, The State University of New Jersey. The principal investigator is Coral Omene, MD, PhD at Cancer Institute of New Jersey Rutgers. The trial plans to enroll 16 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.